WAVE Life Sciences (NASDAQ: WVE) has recently received a number of price target changes and ratings updates:
- 5/4/2026 – WAVE Life Sciences had its price target lowered by Citigroup Inc. from $30.00 to $24.00. They now have a “buy” rating on the stock.
- 5/2/2026 – WAVE Life Sciences was upgraded by Wall Street Zen from “strong sell” to “hold”.
- 4/30/2026 – WAVE Life Sciences had its price target lowered by Canaccord Genuity Group Inc. from $52.00 to $43.00. They now have a “buy” rating on the stock.
- 4/29/2026 – WAVE Life Sciences is now covered by Truist Financial Corporation. They set a “buy” rating and a $15.00 price target on the stock.
- 4/20/2026 – WAVE Life Sciences had its “sell (d-)” rating reaffirmed by Weiss Ratings.
- 4/14/2026 – WAVE Life Sciences had its price target lowered by HC Wainwright from $30.00 to $18.00. They now have a “buy” rating on the stock.
- 4/12/2026 – WAVE Life Sciences was downgraded by Wall Street Zen from “sell” to “strong sell”.
- 3/27/2026 – WAVE Life Sciences had its price target lowered by Bank of America Corporation from $38.00 to $21.00. They now have a “buy” rating on the stock.
- 3/27/2026 – WAVE Life Sciences had its price target lowered by Wells Fargo & Company from $27.00 to $13.00. They now have an “overweight” rating on the stock.
- 3/25/2026 – WAVE Life Sciences was upgraded by Truist Financial Corporation to “strong-buy”.
- 3/25/2026 – WAVE Life Sciences had its price target raised by Mizuho from $22.00 to $27.00. They now have an “outperform” rating on the stock.
Insiders Place Their Bets
In other WAVE Life Sciences news, insider Chris Francis sold 33,194 shares of the firm’s stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $15.05, for a total value of $499,569.70. Following the completion of the sale, the insider directly owned 61,867 shares of the company’s stock, valued at $931,098.35. This trade represents a 34.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Company insiders own 24.30% of the company’s stock.
The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.
See Also
- Five stocks we like better than WAVE Life Sciences
- Karman: Defense Darling’s Outlook Strengthens After 40% Drop
- Aeluma’s Post-Earnings Dip Creates a Buying Opportunity
- Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record Highs
- 2 Ways to Play the Big Pharma Patent Cliff
Receive News & Ratings for WAVE Life Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WAVE Life Sciences Ltd and related companies with MarketBeat.com's FREE daily email newsletter.
